This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record.
The GLP-1 commercial map, where the binding constraint is access and reimbursement rather than which manufacturer wins on efficacy.
The full text now lives in the updated version linked above. This page is kept online so that existing links and bookmarks continue to work; its body was replaced to avoid publishing the same article at two addresses.
Information only — not investment advice, and not medical advice.
Uthando Nethemba 
Leave a comment